2008 Annual Meeting Abstracts
Prostate Cancer Treated with Cryoablation Therapy: A Three Year Review of Results
James C Nederostek, Bethany Barone*, Robert W. Given
Eastern Virginia Medical School, Norfolk, VA
Introduction: Since the early 1990’s, cryosurgery has been used for the management of localized prostate cancer with reasonable cancer control rates. Current cryoablative technology involves third-generation instruments that have reduced morbidity. We performed a retrospective study of patients treated with prostate cryosurgery at a single institution using the Cryocare CS device to determine biochemical disease-free recurrence rates with short-term follow-up.
Methods: From 2003 to 2007, we retrospectively analyzed the data from 156 patients treated by cyroablation for the primary treatment of T1 to T3 prostate cancer. Our focus was on determining overall biochemical disease-free recurrence survival and how it might be affected with pre-treatment hormone therapy.
Results: The median follow-up for our study was 20 months, with 88% of patients nadiring < 0.5. Using a nadir plus 2 ng/dL definition, Kaplan-Meier analysis demonstrated a biochemical disease-free survival rate of 93% and 81% for 1 year and 3 year groups respectively. When comparing the survival difference with neo-adjuvant hormone therapy versus no hormone therapy, the rate was 90.5% and 95.2% at 1 year, and 87.2% and 77.8% at 3 years respectively, which was not statistically significant. The majority of complications were minor with a rate of 13%.
Conclusions: Our results are comparable to other series with regard to short-term cancer control. Neo-adjuvant hormone therapy was not statistically significant with overall survival. The complication rate was low using third-generation cryoablative technology. This further justifies the use of cryosurgery for the management of localized prostate cancer.
